Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxychloroquine in Sudden Sensorineural Hearing Loss
NCT06467526Phase 2Recruiting
- Sponsor
- Chang Gung Memorial Hospital
- Start
- Sep 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of hydroxychloroquine in sudden sensorineural hearing loss (SSHL) (2 arms), sponsored by Chang Gung Memorial Hospital. Primary endpoint: Pure Tone Audiogram at 3 months. Started Sep 2024; status: recruiting.
02
Drugs
hydroxychloroquine
03
Conditions
sudden sensorineural hearing loss (SSHL)
Beyond the preview
Go deeper on NCT06467526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06467526.